India Pharma Market Grows 11.5% in June: Report

India’s pharma market grew strongly by 11.5 per cent in June 2025 compared to the same month last year, a new report said on Wednesday.

In June 2024, the growth was 7 per cent, and in May 2025, it was 6.9 per cent, said Motilal Oswal Financial Services in its monthly report.

The growth was mainly because of higher sales in respiratory, cardiac, central nervous system (CNS), and pain therapies. These segments performed better than the overall market.

Acute therapies grew by 11 per cent in June, higher than 7 per cent in June last year and 5 per cent in May this year. Anti-infective medicines also showed good growth compared to earlier months.

The report said the market growth in the last 12 months was driven by higher prices (4.2 per cent), new product launches (2.3 per cent), and more volume sales (1.5 per cent).

The pharma industry also saw 8 per cent growth in moving annual turnover (MAT).

Chronic therapies grew 10 per cent year-on-year, while acute therapies grew 6.8 per cent. Cardiac therapies saw the highest growth at 11.8 per cent, followed by CNS at 9.1 per cent and dermatology at 8.6 per cent.

However, anti-infectives and respiratory segments grew less than the market average.

Acute therapies made up 60.8 per cent of the total pharma market as of June, with 6.8 per cent growth.

The report also said Indian pharma companies did better than multinational companies (MNCs) in June. Indian companies hold 84 per cent of the market share and grew by 11.6 per cent, while MNCs grew 11.2 per cent.